Cargando…
Status of TMPRSS2–ERG fusion in prostate cancer patients from India: correlation with clinico-pathological details and TMPRSS2 Met160Val polymorphism
BACKGROUND: Prostate cancer (PCa) shows considerable clinical heterogeneity that has been primarily attributed to variable molecular alterations. TMPRSS2–ERG fusion is one such molecular subtype that has been associated with predominantly poor prognosis. More recently, a single nucleotide polymorphi...
Autores principales: | Bhanushali, Aparna, Rao, Pranesh, Raman, Vaishnavi, Kokate, Prajakta, Ambekar, Asawari, Mandva, Swarna, Bhatia, Simi, Das, B.R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Asian Pacific Prostate Society
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251948/ https://www.ncbi.nlm.nih.gov/pubmed/30505817 http://dx.doi.org/10.1016/j.prnil.2018.03.004 |
Ejemplares similares
-
Initial study on TMPRSS2 p.Val160Met genetic variant in COVID-19 patients
por: Wulandari, Laksmi, et al.
Publicado: (2021) -
Quantitative Expression of TMPRSS2 Transcript in Prostate Tumor Cells Reflects TMPRSS2-ERG Fusion Status
por: Mwamukonda, Kuwong, et al.
Publicado: (2009) -
Significance of the TMPRSS2:ERG gene fusion in prostate cancer
por: Wang, Zhu, et al.
Publicado: (2017) -
5′ UTR Control of Native ERG and of Tmprss2:ERG Variants Activity in Prostate Cancer
por: Zammarchi, Francesca, et al.
Publicado: (2013) -
Functional antagonism of TMPRSS2-ERG splice variants in prostate cancer
por: Rastogi, Anshu, et al.
Publicado: (2014)